Pharvaris N.V annual stock-based compensation
2018
2019
2020
2021
2022
2023
2024
2025
Pharvaris N.V Stock-Based Compensation Growth & History (PHVS)
Pharvaris N.V's stock-based compensation was €11.2M for fiscal 2025.
View full Pharvaris N.V company overviewPharvaris N.V annual stock-based compensation history
| Fiscal year | Period ended | Stock-based compensation | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | €11.2M | €700,000 | +6.67% |
| 2024 | 2024-12-31 | €10.5M | €4.3M | +69.35% |
| 2023 | 2023-12-31 | €6.2M | −€1.4M | −18.42% |
| 2022 | 2022-12-31 | €7.6M | €600,000 | +8.57% |
| 2021 | 2021-12-31 | €7.0M | €5.6M | +396.42% |
| 2020 | 2020-12-31 | €1.4M | €1.3M | +1310.86% |
| 2019 | 2019-12-31 | €99,946 | €0 | 0.00% |
| 2018 | 2018-12-31 | €99,946 | — | — |
Pharvaris N.V quarterly stock-based compensation
Q2.21
Q2.22
Q2.23
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Stock-based compensation | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | €6.6M | €1.1M | +20.63% |
| Q1 2026 | 2026-03-31 | €4.9M | €770,192 | +18.66% |
| Q4 2025 | 2025-12-31 | €4.5M | — | — |
| Q3 2025 | 2025-09-30 | €4.9M | — | — |
| Q2 2025 | 2025-06-30 | €5.5M | — | — |
| Q1 2025 | 2025-03-31 | €4.1M | — | — |
| Q2 2023 | 2023-06-30 | €2.7M | −€425,912 | −13.55% |
| Q2 2022 | 2022-06-30 | €3.1M | €1.4M | +77.29% |
| Q2 2021 | 2021-06-30 | €1.8M | — | — |
Pharvaris N.V stock-based compensation trends
Over the last five fiscal years, Pharvaris N.V's stock-based compensation increased from €1.4M to €11.2M, a change of €9.8M. The latest reported quarter, Q2 2026, shows €6.6M.
About the metric
What stock-based compensation means
Stock-based compensation is the expense associated with equity awards such as restricted stock and employee options. It is a non-cash expense when recognized, but it can dilute existing shareholders unless offset by share repurchases.
Calculation and source
SEC-reported stock-based compensation
TickerStat standardizes share-based compensation reported in company SEC filings. The history shows recognized compensation expense or its cash-flow-statement adjustment, not the grant-date value of new awards or a forecast of future dilution. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Pharvaris N.V source filings ↗